BRNS VS UNH Stock Comparison
Performance
BRNS10/100
10/100
BRNS returned -42.40% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
UNH10/100
10/100
UNH returned 6.83% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Earnings
BRNS100/100
100/100
BRNS has missed earnings 1 times in the last 20 quarters.
UNH100/100
100/100
UNH has missed earnings 0 times in the last 20 quarters.
Volatility
BRNS50/100
50/100
BRNS has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.
UNH49/100
49/100
UNH has had a lower than average amount of volatility over the last 12 months giving it a score of 49 of 100.
Analyst Price Targets
BRNS
"Analyst Price Targets" not found for BRNS
UNH88/100
88/100
22 analysts offer 12-month price targets for UNH. Together, they have an average target of 562.97, the most optimistic target put UNH at 650 within 12-months and the most pessimistic has UNH at 442.
Technicals
BRNS
"Technicals" not found for BRNS
UNH89/100
89/100
UNH receives a 89 of 100 based on 14 indicators. 12 are bullish, 1 are bearish.
Profit
BRNS
"Profit" not found for BRNS
UNH81/100
81/100
Out of the last 20 quarters, UNH has had 20 profitable quarters and has increased their profits year over year on 11 of them.
Dividend
BRNS
"Dividend" not found for BRNS
UNH57/100
57/100
UNH's most recent dividend was $0.90 per share, based on a share price of $540.46. It was a payout ratio of 28.49% compared to their total earnings.
All score calculations are broken down here to help you make more informed investing decisions
Barinthus Biotherapeutics plc American Depositary Shares Summary
Nasdaq / BRNS
Healthcare
Biotechnology
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.
UNITEDHEALTH GROUP INCORPORATED (Delaware) Summary
New York Stock Exchange / UNH
Healthcare
Medical - Healthcare Plans
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage and well-being services to individuals age 50 and older addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children's health insurance and health care programs; health and dental benefits; and hospital and clinical services. The OptumHealth segment provides access to networks of care provider specialists, health management services, care delivery, consumer engagement, and financial services. This segment serves individuals directly through care delivery systems, employers, payers, and government entities. The OptumInsight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The OptumRx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and compounding pharmacy, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was incorporated in 1977 and is based in Minnetonka, Minnesota.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare BRNS to other companies in the same or a similar industry.